Filing Details

Accession Number:
0001209191-14-078437
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-12-30 19:31:49
Reporting Period:
2014-12-26
Filing Date:
2014-12-30
Accepted Time:
2014-12-30 19:31:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1103021 Biodelivery Sciences International Inc BDSI Pharmaceutical Preparations (2834) 352089858
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1066040 Jr E Francis Odonnell C/O Biodelivery Sciences Intl, Inc.
801 Corporate Center Drive, Suite 210
Raleigh NC 27607
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-12-26 200,000 $0.00 2,050,490 No 4 J Indirect By HCG II, LLC
Common Stock Disposition 2014-12-26 50,000 $12.01 2,000,490 No 4 S Indirect By HCG II, LLC
Common Stock Disposition 2014-12-26 20,000 $11.96 105,301 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 J Indirect By HCG II, LLC
No 4 S Indirect By HCG II, LLC
No 4 S Direct
Footnotes
  1. The distribution was made to a member of Hopkins Capital Group II, LLC, who is not an affiliate of the issuer and for no consideration.
  2. The shares are owned by Hopkins Capital Group II, LLC. The Reporting Person is the manager of Hopkins Capital Group II, LLC. Filing of this statement shall not be deemed an admission by the Reporting Person that he beneficially owns the securities held by Hopkins Capital Group II, LLC. The Reporting Person disclaims ownership of all securities held by Hopkins Capital Group II, LLC.
  3. On December 26, 2014, Hopkins Capital Group II, LLC sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $12.01. The highest sale price for the Common Stock was $12.30 per share and the lowest sale price was $11.86 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.